Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern
Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern
apnews.com
Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern
Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved Leqembi from Japanese drugmaker Eisai.